| Market Cap | 101.05M | P/E | - | EPS this Y | 28.60% | Ern Qtrly Grth | - |
| Income | -22.62M | Forward P/E | -4.52 | EPS next Y | -15.00% | 50D Avg Chg | -19.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 55.00% |
| Dividend | N/A | Price/Book | 2.07 | EPS next 5Y | - | 52W High Chg | -48.00% |
| Recommedations | 1.60 | Quick Ratio | 3.55 | Shares Outstanding | 62.55M | 52W Low Chg | 257.00% |
| Insider Own | 4.02% | ROA | -23.83% | Shares Float | 38M | Beta | 1.13 |
| Inst Own | 44.16% | ROE | -44.91% | Shares Shorted/Prior | 1.64M/1.37M | Price | 2.17 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 1,123,456 | Target Price | 10.13 |
| Oper. Margin | - | Earnings Date | Nov 5 | Volume | 198,968 | Change | -3.12% |
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
| Ladenburg Thalmann | Buy | Sep 16, 24 |
| Oppenheimer | Outperform | May 7, 24 |
| Cantor Fitzgerald | Overweight | Apr 1, 24 |
| Mizuho | Neutral | Mar 27, 24 |
| Oppenheimer | Outperform | Mar 20, 24 |
| Cantor Fitzgerald | Overweight | Sep 7, 23 |
| Mizuho | Neutral | Jun 16, 23 |
| Ladenburg Thalmann | Buy | May 30, 23 |
| Cantor Fitzgerald | Overweight | May 9, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Jones William Benton | See Remarks See Remarks | Dec 20 | Buy | 0.79 | 20,000 | 15,800 | 133,773 | 12/20/22 |
| MILLER RICHARD A MD | President and CEO President and CEO | Sep 28 | Buy | 0.7628 | 25,000 | 19,070 | 1,394,405 | 09/28/22 |
| MILLER RICHARD A MD | President and CEO President and CEO | Sep 20 | Buy | 0.82 | 20,000 | 16,400 | 1,369,405 | 09/20/22 |
| MILLER RICHARD A MD | President and CEO President and CEO | Jun 24 | Buy | 1.01 | 10,000 | 10,100 | 1,349,405 | 06/28/22 |
| MILLER RICHARD A MD | President and CEO President and CEO | Jun 02 | Buy | 0.99 | 5,890 | 5,831 | 1,339,405 | 06/06/22 |
| LEA LEIV | Chief Financial Offi.. Chief Financial Officer | Mar 16 | Buy | 1.6 | 49,038 | 78,461 | 99,238 | 03/17/22 |
| MILLER RICHARD A MD | President and CEO President and CEO | Mar 15 | Buy | 1.53 | 30,000 | 45,900 | 1,318,515 | 03/17/22 |